THE MONTHLY January 2020

The Office for National Statistics (ONS) is due to publish its most up-to-date survey on share ownership in mid-January, which identifies the beneficial owners and decision- makers of the stock market. Hardman & Co has worked together with the share analysis service, Argus Vickers, to jointly produce its own survey, which anticipates the conclusions of the ONS survey but goes into much greater detail. Our work does not use a sample of 200 quoted companies as the ONS historically has, but rather

HUTCHMED - China NDA withdrawn for Fruquintinib in gastric cancer

HUTCHMED has announced that it has it has voluntarily withdrawn its new drug application (NDA) in China for fruquintinib in second-line gastric cancer. The company cited that it became clear from its dialogue with the Chinese regulators, and its external committee members, that the overall survival results from the phase III FRUTIGA trial, in their current format, could not serve as the basis of an approval, and that further work needs to be undertaken. Whilst the news is clearly disappointing,

MNOV: Phase 3 ALS Readout in 2025

On August 8, 2024, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2024. The company is conducting a Phase 3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which includes 12 months of double-blind treatment plus a six-month open label extension period. The primary endpoint is change from baseline in ALSFRS-R at Month 12 and survival time. We anticipate a data readout in 2025. The company is also conducting a Phase 2 trial of

ENSC: Substantial Federal Funds Granted

Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company announced that it has received a $14 million grant from the NIH for the continued development of its abuse deterrent opioid-PF614-MPAR.

Hybridan Small Cap Feast 16/12/2021

Joiners DSW Capital plc (DSW.L) a profitable, fast growing, mid-market, challenger professional services network joins AIM. DSW operates a licencing model and licences the DSW and associated brand names in return for a royalty based on a percentage of fee income. Public Policy Holding Company (PPHC.L) leading bi-partisan, full-service US government affairs business joins AIM. Through its wholly-owned companies, PPHC operates a portfolio of independent firms that offer public affairs, crisis mana

Hybridan Small Cap Feast - 14 Jul 23

14th July 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objecti

Belluscura AGM Update

Belluscura has released an AGM trading update that reveals strong sales momentum has continued through the summer with consecutive record revenues set in June and July of $0.5m and $0.7m respectively, as the X-PLOR finds broader market acceptance and after a soft launch of the new DISCOV-R.

Morning Note – 27 June 2024

Morning Note – 27 August 2024

Hybridan Small Cap Feast 30 Nov 23

30th November 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj

Hybridan Small Cap Feast - 09 May 2024

9th May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: E-Therapeutics (ETX.L) has left AIM. Advanced Oncotherapy (AVO.L) has left AIM. What’s baking in the oven? ** Potential**** Initial Public Offerings: 7th May: Time To ACT plc, an engineering business focused on technology for the energy transition sector, has a

Hybridan Small Cap Feast - 28 May 24

28th May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: Accrol Group Holdings (ACRL.L) has left AIM. China Nonferrous Gold Limited (CNG.L) has left AIM. What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 7th May: Time To ACT plc, an engineering business focused o

Hybridan Small Cap Feast - 16 July 2024

16th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to co

Allenby Capital TMT Update - 18.03.24 - MWE.L, CHSS.L, CPX.L, BVC.L, SSIT.L

Please find below our weekly update covering themes that we feel that are of interest to investors and participants in the small and mid-cap TMT sector as well as commentary on recent newsflow.

Shield Therapeutics - AOP Milestone Monetisation gives comfort on cash position

STX has done a deal with its major shareholder, AOP Health International Management, under which it will get a $5.7m cash advance, to be paid back by the future milestone payment ($11.4m) that STX expects to receive upon the approval of Accrufer in China in 2026. Although the payback terms are favourable to AOP, we would not expect it to further invest if it did not have a clear line of sight to payback via the China approval, and more broadly STX’s ability to become profitable. In today’s relea